Search research articles
Contact Us
Filters
Showing results (131-140 of 170) with videos related to
Page
of 17
Sort By:
Neurobiology of Aging
|
March 30, 2021
LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease
Yuri L Sosero, Eric Yu, Lynne Krohn, et al.
Drug Safety
|
May 9, 2003
Benefits and risks of pharmacological treatments for essential tremor
Kelly E Lyons, Rajesh Pahwa, Cynthia L Comella, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 16, 2004
Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations
Lorraine N Clark, Shehla Afridi, Helen Mejia-Santana, et al.
NPJ Parkinson'S Disease
|
April 26, 2016
<i>SCARB2</i> variants and glucocerebrosidase activity in Parkinson's disease
Roy N Alcalay, Oren A Levy, Pavlina Wolf, et al.
Brain : a Journal of Neurology
|
June 29, 2015
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations
Roy N Alcalay, Oren A Levy, Cheryl C Waters, et al.
Journal of Neurology
|
September 5, 2021
COVID-19 manifestations in people with Parkinson's disease: a USA cohort
Yaqian Xu, Matthew Surface, Amanda K Chan, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
September 25, 2014
Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain
Joanna S Fowler, Jean Logan, Nora D Volkow, et al.
Plos One
|
May 2, 2015
Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease
Lorraine N Clark, Robin Chan, Rong Cheng, et al.
European Journal of Medical Genetics
|
May 30, 2018
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease
Jennifer A Ruskey, Lior Greenbaum, Léanne Roncière, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
November 28, 2013
Designing clinical trials for dystonia
Wendy R Galpern, Christopher S Coffey, Alberto Albanese, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 170) with videos related to
Sort By:
Page
of 17
Neurobiology of Aging
|
March 30, 2021
LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease
Yuri L Sosero, Eric Yu, Lynne Krohn, et al.
Drug Safety
|
May 9, 2003
Benefits and risks of pharmacological treatments for essential tremor
Kelly E Lyons, Rajesh Pahwa, Cynthia L Comella, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 16, 2004
Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations
Lorraine N Clark, Shehla Afridi, Helen Mejia-Santana, et al.
NPJ Parkinson'S Disease
|
April 26, 2016
<i>SCARB2</i> variants and glucocerebrosidase activity in Parkinson's disease
Roy N Alcalay, Oren A Levy, Pavlina Wolf, et al.
Brain : a Journal of Neurology
|
June 29, 2015
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations
Roy N Alcalay, Oren A Levy, Cheryl C Waters, et al.
Journal of Neurology
|
September 5, 2021
COVID-19 manifestations in people with Parkinson's disease: a USA cohort
Yaqian Xu, Matthew Surface, Amanda K Chan, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
September 25, 2014
Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain
Joanna S Fowler, Jean Logan, Nora D Volkow, et al.
Plos One
|
May 2, 2015
Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease
Lorraine N Clark, Robin Chan, Rong Cheng, et al.
European Journal of Medical Genetics
|
May 30, 2018
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease
Jennifer A Ruskey, Lior Greenbaum, Léanne Roncière, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
November 28, 2013
Designing clinical trials for dystonia
Wendy R Galpern, Christopher S Coffey, Alberto Albanese, et al.
Page
of 17